Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations from the EXTRIP workgroup
Marc Ghannoum,Sophie Gosselin,Robert S. Hoffman,Valery Lavergne,Bruno Mégarbane,Hossein Hassanian-Moghaddam,Maria Rif,Siba Kallab,Steven Bird,David M. Wood,Darren M. Roberts,Badria Alhatali,Kurt Anseeuw,Ingrid Berling,Josée Bouchard,Timothy E. Bunchman,Diane P. Calello,Paul K. Chin,Kent Doi,Tais Galvao,David S. Goldfarb,Lotte C. G. Hoegberg,Sofia Kebede,Jan T. Kielstein,Andrew Lewington,Yi Li,Etienne M. Macedo,Rob MacLaren,James B. Mowry,Thomas D. Nolin,Marlies Ostermann,Ai Peng,Jean-Philippe Roy,Greene Shepherd,Anitha Vijayan,Steven J. Walsh,Anselm Wong,Christopher Yates,for the EXTRIP Workgroup
DOI: https://doi.org/10.1186/s13054-022-04227-2
IF: 15.1
2023-02-12
Critical Care
Abstract:Ethylene glycol (EG) is metabolized into glycolate and oxalate and may cause metabolic acidemia, neurotoxicity, acute kidney injury (AKI), and death. Historically, treatment of EG toxicity included supportive care, correction of acid–base disturbances and antidotes (ethanol or fomepizole), and extracorporeal treatments (ECTRs), such as hemodialysis. With the wider availability of fomepizole, the indications for ECTRs in EG poisoning are debated. We conducted systematic reviews of the literature following published EXTRIP methods to determine the utility of ECTRs in the management of EG toxicity. The quality of the evidence and the strength of recommendations, either strong ("we recommend") or weak/conditional ("we suggest"), were graded according to the GRADE approach. A total of 226 articles met inclusion criteria. EG was assessed as dialyzable by intermittent hemodialysis (level of evidence = B) as was glycolate (Level of evidence = C). Clinical data were available for analysis on 446 patients, in whom overall mortality was 18.7%. In the subgroup of patients with a glycolate concentration ≤ 12 mmol/L (or anion gap ≤ 28 mmol/L), mortality was 3.6%; in this subgroup, outcomes in patients receiving ECTR were not better than in those who did not receive ECTR. The EXTRIP workgroup made the following recommendations for the use of ECTR in addition to supportive care over supportive care alone in the management of EG poisoning (very low quality of evidence for all recommendations): i) Suggest ECTR if fomepizole is used and EG concentration > 50 mmol/L OR osmol gap > 50; or ii) Recommend ECTR if ethanol is used and EG concentration > 50 mmol/L OR osmol gap > 50; or iii) Recommend ECTR if glycolate concentration is > 12 mmol/L or anion gap > 27 mmol/L; or iv) Suggest ECTR if glycolate concentration 8–12 mmol/L or anion gap 23–27 mmol/L; or v) Recommend ECTR if there are severe clinical features (coma, seizures, or AKI). In most settings, the workgroup recommends using intermittent hemodialysis over other ECTRs. If intermittent hemodialysis is not available, CKRT is recommended over other types of ECTR. Cessation of ECTR is recommended once the anion gap is < 18 mmol/L or suggested if EG concentration is < 4 mmol/L. The dosage of antidotes (fomepizole or ethanol) needs to be adjusted during ECTR.
critical care medicine